Multicenter clinical trial using an accelerated streptokinase regimen in patients with acute myocardial infarction.
To observe the clinical efficacy and safety of intravenous thrombolytic therapy using an accelerated streptokinase (SK) regimen in acute myocardial infarction (AMI). Data were collected from 40 hospitals during April 1996 to July 1997. Clinical therapeutic efficacy, five-week mortality, and adverse events were analyzed in 527 patients with AMI treated with an accelerated SK regimen (1.5 million IU within 30 min). The reperfusion rate of infarct-related arteries (IRAs) was 79.7% (421/528) assessed by clinical signs. The total mortality in the first 5 weeks was 6.6% (35/527). The incidence of allergic reactions and hypotension was 3.8% (20/528) and 4.2% (22/528), respectively. The incidence of bleeding was 2.7% (14/528), including cerebral bleeding 0.8% (4/528) and other major bleeding 0.8% (4/528). Intravenous accelerated SK therapy can markedly improve reperfusion rate without increasing adverse events such as bleeding, allergic reactions and hypotension.